May 18, 2016 6:37am

 

Despite writing about the negatives, I attempt to find the positive in “our’ universe but, to understand the probabilities of the upside - one has to analyze the factors of context related to negative outcomes

 

Companies mentioned: BLUE and CYTX  

 

Where are today’s markets going?  Don’t miss access to this morning’s actionable information.

Subscription sign-up … http://www.regmedinvestors.com/create-account

 

 

I say today what others won't, so you can do what others can't; whether information or intelligence is good, bad or somewhere in between – it defines the who, when, where, which and what of it …

 

 

Dow futures are DOWN -0.30% and NASDAQ futures are DOWN -0.24% - update

 

U.S. stock futures on Wednesday are trading down, as investors avoided big bets ahead of a release that could hint at when the next interest-rate hike will hit.

European markets traded lower, amid higher trade in the oil price, as comments from U.S. Fed officials suggested a rate hike could come sooner than expected.

Asian markets retreated as traders moved their chips amid concerns the U.S. Federal Reserve may hike interest rates soon, with Japan's shares ending a tad down after topsy-turvy trade.

 

Data docket: Minutes from the Federal Reserve’s last policy meeting are due at 2 p.m. ET. The stock market also could move on a weekly reading on U.S. oil supplies, which is expected at 10:30 a.m. ET.

 

 

The stem, cell and gene therapy regenerative medicine (SCGT&RM) sector closed NEGATIVE on Tuesday, POSITIVE on Monday, NEGATIVE on Friday, Thursday and last Wednesday.

 

The stem, cell and gene therapy regenerative medicine sector’s record after the last 5 days (of 43 covered companies):

  • Tuesday closed NEGATIVE with 26 decliners, 13 advancers and 4 flats;
  • Monday closed POSITIVE with 12 decliners, 27 advancers and 4 flats;
  • Friday closed NEGATIVE with 22 decliners, 15 advancers and 6 flats;
  • Thursday closed NEGATIVE with 36 decliners, 5 advancers and 2 flats;
  • Last, Wednesday closed NEGATIVE with 30 decliners, 11 advancers and 2 flats;

 

 

A reminder from Tuesday’s closing post, “Sector stocks opened negative, flipped barely positive at the mid-day and closed negative. The consequence of dependence on blurred expectation and Murphy’s Law.”

  • My days are filled reading market commentary, breaking news by financial media and many pundits, yet, there seems to be a sense of apathy.

The SCGT&RM sector has seen a slowing flow of buyers as exchange-traded funds have emerged as important hedging and trading vehicles for institutions and hedge funds.

  • My aim is to project the probabilities, not to be a crystal ball.

I am an analyst and a journalist who focuses on the stem, cell and gene therapy and regenerative medicines stocks for the "short and near" term of investor’s portfolios.

  • Some pundits, a few I-Bank analysts and “other” prognosticators tend to mislead investors, giving them a sense of security or causing them to adopt their view of approaches to investment but, how do they define their INDEPENDENCE?

MY mission is to provide readers with daily, insight of the cell and gene therapy, regenerative medicine and stem cell research companies.  I provide time sensitive intelligence and metrics to define the ever changing field of regenerative medicine.

  • I believe in bringing a qualification to news and a pricing metric to light like an umbrella in the rain!

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?  Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed Tuesday down -0.96% and is UP +0.03% in Wednesday’s pre-market;

 

  • The SPDR S&P Biotech ETF (XBI) closed Tuesday down -0.78%  and is FLAT in Wednesday’s  pre-market;

 

  • NASDAQ Biotechnology (NBI) closed up Tuesday -0.90%;

 

  • The Health Care Select Sector SPDR ETF (XLV) closed Tuesday down -1.04% and is DOWN -0.03% in Wednesday’s pre-market;

 

  • The iShares Russell 2000 (IWM) closed Tuesday down -1.59% and is DOWN -0.10% in Wednesday’s pre-market.

 

 

Companies in the spotlight;

Cytori (CYTX) closed UP +$0.88 to $3.33. Cytori Therapeutics’ (CYTX) volume is up 86.7% <1.093 M shares as compared to the 3 month average of 145.3 K shares> and the shares … are up +35.92% as investors take positions to qualify to receive one subscription right for each common share owned.  The stockholder of record date is Friday May 20 but the company is advising investors to buy shares no later than 4:00 pm ET today to ensure inclusion.  The after-market indication is +$0.11 – SELL to BUY;

bluebird bio (BLUE) closed UP +$0.18 to $38.91 after Monday’s $0.27. After a week of swings, Friday’s $38.46, Thursday’s $36.20, Wednesday’s $38.62, Tuesday’s $40.80 and last Monday’s $41.05 – the range is anyone’s question.  The after-market indication is -$0.10 – Maintaining SELL;

 

Opinions expressed are those of the author and are subject to change, and are not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.